Pharmacokinetics and Pharmacodynamics of Lansoprazole in Children with Gastroesophageal Reflux Disease
David A. Gremse(University of South Alabama), Linda Book(University of Utah), Betsy Pilmer(Abbott Fund), Thirumazhisai S. Gunasekaran, Vasundhara Tolia(Children's Hospital of Michigan), Harland S. Winter(Massachusetts General Hospital), Yi‐Lin Chiu(National Defense University), Michael D. Karol(Forest Products Laboratory), Wei‐Jian Pan(Forest Products Laboratory)
Cited by 31
Related Papers
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
|Journal of Crohn s and Colitis|2014|1.1k
Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in Children
|Gastroenterology|2006|872
Evaluation, Diagnosis, and Treatment of Gastrointestinal Disorders in Individuals With ASDs: A Consensus Report
|PEDIATRICS|2010|870
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
Children with early-onset inflammatory bowel disease (IBD): Analysis of a pediatric IBD consortium registry
|The Journal of Pediatrics|2005|571